Pemigatinib
- Generic Name
- Pemigatinib
- Brand Names
- Pemazyre
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F2N5O4
- CAS Number
- 1513857-77-6
- Unique Ingredient Identifier
- Y6BX7BL23K
- Background
Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide varie...
- Indication
Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
...
- Associated Conditions
- Refractory Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Relapsed Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas
- Associated Therapies
- -
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
- Conditions
- Interventions
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mehmet Akce
- Target Recruit Count
- 38
- Registration Number
- NCT06728410
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 40
- Registration Number
- NCT06653777
- Locations
- 🇫🇷
Institut Curie, Paris, France
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 30
- Registration Number
- NCT06551896
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06439485
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Lund University Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06389799
- Locations
- 🇳🇴
Oslo University Hospital HF, Oslo, Norway
🇸🇪Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Skåne University Hospital, Lund, Sweden
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06302621
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 27
- Registration Number
- NCT06300528
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06022289
- Locations
- 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 23
- Registration Number
- NCT05997459
- Locations
- 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 30
- Registration Number
- NCT05913661
- Locations
- 🇨🇳
Lei Zhang, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.